The latest update to the MySejahtera mobile application now allows Malaysians to purchase Covid-19 self-test kits, locate a nearby health screening facility and directly get in touch with emergency services.
Through the app, denizens are currently given the option to purchase three different types of Covid-19 test kits via the Pharma2u e-store and also allow corporations to buy them in bulk;
- Salixium Covid-19 Home Self Test Rapid Antigen Test Kit (RM39.90)
- Gmate Covid-19 Salive Home Self Test Saliva Rapid Antigen Kit (RM39.90)
- JusChek Covid-19 Antigen Rapid Test (RM35)
The Pharma2u website also lists a fourth test kit available for purchase;
- Longsee Covid-19 Home Self Test Rapid Antigen Kit (RM41)
Just simply open your MySejahtera app to be prompted with an ‘update now’ notification and follow the instructions.
After the update, three new icons should be available on your app.
Just remember that clicking on the Emergency (SOS) icon will connect you directly to 999, so it’s best not to abuse it.
Dear users, we have updated the mobile app with enhanced features earlier this morning. Please update your app to the latest version. Close and reopen the app after update and you will be able to experience the latest features.— MySejahtera (@my_sejahtera) July 30, 2021
Digital consent form
The MySejahtera update also comes with a new consent form that needs to be filled up by those receiving appointments for their first dose of the Covid-19 vaccines.
According to the Special Committee On Covid-19 Vaccine Supply (JKJAV), for people who’ve already received their first vaccine shot and signed their consent form manually, you don’t need to fill up this new digital form.
New feature on @my_sejahtera.— Vaksin COVID-19 🇲🇾 (@JKJAVMY) July 30, 2021
This digital consent form only applies to first dose appointment.
For those who have received their first dose vaccine and have signed their consent form manually, you don’t need to fill up this digital form. pic.twitter.com/MpfmOwcTHj
Share your thoughts with us on TRP’s Facebook, Twitter, and Instagram.